Condition: Refractory Chronic Cough · Sponsor: Bellus Health Inc. - a GSK company
This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 2b adaptive dose-finding study of BLU-5937 in participants with Refractory Chronic Cough (RCC).
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Phoenix Medical Research Inc | Peoria, Arizona, United States | — |
| Little Rock Allergy and Asthma Clinical Research Center | Little Rock, Arkansas, United States | — |
| Southern California Institute For Respiratory Diseases, Inc | Los Angeles, California, United States | — |
| Allergy and Asthma Associates of Southern California | Mission Viejo, California, United States | — |
| California Medical Research Associates, Inc. | Northridge, California, United States | — |
| Allergy Associates Medical Group Inc. | San Diego, California, United States | — |
| Allergy and Asthma Associates of Santa Clara Valley Research Center | San Jose, California, United States | — |
| Colorado Allergy and Asthma Centers | Denver, Colorado, United States | — |
| St. Francis Medical Institute | Clearwater, Florida, United States | — |
| Floridian Clinical Research | Hialeah, Florida, United States | — |
| Sweet Hope Research Specialty, Inc. | Hialeah, Florida, United States | — |
| Sher Allergy Specialist/Center for Cough | Largo, Florida, United States | — |
+ 104 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04678206